New York, Oct 16 (IANS): Amid the rush to find quick treatments for Covid-19 last year, the world saw a global race to find new stem cell-based treatments. Now, researchers report that such therapies were filled with violations of government regulations, inflated medical claims and distorted public communication.
There are reports of patients suffering physical harm -- including blindness and death -- from unproven stem cell therapies.
"Efforts to rapidly develop therapeutic interventions should never occur at the expense of the ethical and scientific standards that are at the heart of responsible clinical research and innovation," said lead study author Laertis Ikonomou, associate professor of oral biology at University at Buffalo, New York.
There are clinics offering unproven and unsafe "stem cell" therapies that promise to prevent Covid-19 by strengthening the immune system or improving overall health, the researchers noted in the paper published in the journal Stem Cell Reports.
The findings from preliminary studies on possible stem cell-based Covid-19 treatments are frequently being exaggerated through press releases, social media and uncritical news media reports.
Clinics selling supposed stem cell treatments on a direct-to-consumer basis sometimes use these findings and news reports to exploit the fears of vulnerable patients by unethically advertising the unproven benefits of stem cell treatments to boost the immune system, regenerate lung tissue and prevent transmission of Covid-19, said co-author Leigh Turner from the University of California, Irvine.
"Patients suffer financially as well, as the products range in price from a few thousand to tens of thousands of dollars, and people are often encouraged to receive the expensive treatments every few months," added Ikonomou.
Patients led to believe they are protected against Covid-19 may decide against vaccination, stop wearing masks, cease engaging in physical distancing, or otherwise avoid behaviours intended to promote personal safety and public health.
They may also become less likely to take part in carefully-developed clinical trials conducted by companies that follow ethical standards.
"Scientists, regulators and policymakers must guard against the proliferation of poorly designed, underpowered and duplicative studies that are launched with undue haste because of the pandemic, but are unlikely to provide convincing, clinically meaningful safety and efficacy data," Turner stressed.